论文部分内容阅读
目的探讨凝血酶激活的纤溶抑制物(TAFI)编码区2个单核苷酸多态性位点(505A/G,1040C/T)与2型糖尿病(T2DM)发病及病程进展的相关性。方法应用聚合酶链反应-限制性内切酶片段长度多态性(PCR-RFLP)分析技术检测157例T2DM患者(T2DM组)和140例正常对照者(对照组)的TAFI505A/G、1040C/T两位点的多态性,其中T2DM组根据尿白蛋白排泄量与尿肌酐的比值(ACRs)进一步分型。结果505A/G多态性位点病例组及对照组中各基因型的分布差异无统计学意义,但在1040C/T位点T2DM组T等位基因的频率较对照组明显下降(15.6%vs25.7%,P<0.05),这主要由于病例组T/T纯合子型比例显著下降所致(P<0.05,95%OR0.28,CI0.11~0.70)。但这种显著性差异只呈现在早期T2DM组。结论①TAFI1040C/T基因多态性与T2DM患病危险度存在关联;②T等位基因可能在T2DM早期病情进展中起保护性作用。
Objective To investigate the relationship between the two single nucleotide polymorphisms (505A / G, 1040C / T) in the coding region of thrombin activated fibrinolysis inhibitor (TAFI) and the pathogenesis of type 2 diabetes mellitus (T2DM). Methods The TAFI505A / G and 1040C / G polymorphism were detected in 157 patients with T2DM and 140 healthy controls by PCR-RFLP. T polymorphism, T2DM group according to urinary albumin excretion and urinary creatinine ratio (ACRs) further type. Results There were no significant differences in the genotype distribution between the 505A / G polymorphism loci and the control group, but the frequency of T allele was significantly lower in the T2DM group at 1040C / T (15.6% vs25 .7%, P <0.05). This was mainly attributed to the significant decrease of the proportion of T / T homozygotes in the case group (P <0.05, 95% OR0.28, CI0.11 ~ 0.70). However, this significant difference only showed in the early T2DM group. Conclusion ①TFI1040C / T polymorphism is associated with the risk of T2DM. ②T allele may play a protective role in the early progression of T2DM.